N-hydroxy-4-({6-[4-(3,3,3-trifluoropropyl)phenyl]pyridine-3-yl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide hydrochloride | 701271-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-hydroxy-4-({6-[4-(3,3,3-trifluoropropyl)phenyl]pyridine-3-yl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide hydrochloride
• 英文别名: N-hydroxy-4-[6-[4-(3,3,3-trifluoropropyl)phenyl]pyridin-3-yl]sulfonyloxane-4-carboxamide;hydrochloride
• CAS: 701271-50-3
• 化学式: C₂₀H₂₁F₃N₂O₅S*ClH
• 分子量: 494.919
• InChiKey: PYSAYYAYTBLDDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.49
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-{6-[4-(3,3,3-trifluoro-propyl)-phenyl]-pyridine-3-sulfonyl}-tetrahydro-pyran-4-carboxylic acid (tetrahydro-pyran-2-yloxy)-amide 在 盐酸 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 24.0h， 以60%的产率得到N-hydroxy-4-({6-[4-(3,3,3-trifluoropropyl)phenyl]pyridine-3-yl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide hydrochloride
  参考文献：
  名称：

  [EN] HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS
  [FR] ACIDES ET AMIDES HETEROARYLSULFONYLMETHYL HYDROXAMIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTEASES

  摘要：

  公开号：

  WO2004048368A3

文献信息

• Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
  申请人：——

  公开号：US20040142979A1

  公开（公告）日：2004-07-22

  This invention is directed generally to heteroarylsulfonylmethyl hydroxamic acids and amides that, inter alia, tend to inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to compositions of such compounds; intermediates for the syntheses of such compounds; methods for making such compounds; and methods for treating conditions associated with MMP, tumor necrosis factors (or “TNFs”), and/or aggrecanase activity, particularly pathological conditions.

  本发明一般涉及杂环烷基磺酰甲基羟肟酸和酰胺，该类化合物具有抑制蛋白酶活性（特别是基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或Aggrecanase活性）的倾向。本发明还涉及这些化合物的组合物；合成这些化合物的中间体；制备这些化合物的方法；以及治疗与MMP、肿瘤坏死因子（或“TNFs”）和/或Aggrecanase活性相关的病理情况的方法。
• N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Targacept, Inc.

  公开号：EP1519939A2

  公开（公告）日：2005-04-06
• HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS
  申请人：Pharmacia Corporation

  公开号：EP1565459A2

  公开（公告）日：2005-08-24
• [EN] N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF<br/>[FR] COMPOSES DIAZASPIROCYCLIQUES N-ARYLE ET PROCEDES DE PREPARATION ET D'UTILISATION DE CES DERNIERS
  申请人：TARGACEPT INC

  公开号：WO2004005293A2

  公开（公告）日：2004-01-15

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryldiazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic choligernic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: ( I ) alter the number of nicotinic cholinergic receptors of the brain of the patient, ( ii ) exhibit neuroprotective effects and ( iii ) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).